Hope for bone marrow failure patients

Israeli biotech Pluristem has opened clinical centers in Israel and extended the trial of its stem cell treatment for insufficient hematopoietic recovery following hematopoietic cell transplantation (HCT).  HCT is performed when bone marrow fails for reasons including cancer treatment.

http://www.nasdaq.com/press-release/following-approval-of-israels-ministry-of-health-pluristem-extends-its-trial-of-plxr18-to-treat-20171026-00612

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *